HC Wainwright & Co. Downgrades DICE Therapeutics to Neutral, Announces $48 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar downgraded DICE Therapeutics (NASDAQ:DICE) from Buy to Neutral and set a $48 price target.
June 21, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DICE Therapeutics was downgraded from Buy to Neutral by HC Wainwright & Co. analyst Emily Bodnar, who set a $48 price target.
The downgrade from Buy to Neutral by HC Wainwright & Co. analyst Emily Bodnar indicates a less optimistic outlook for DICE Therapeutics. This could lead to a short-term negative impact on the stock price as investors may perceive the downgrade as a sign of weaker future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100